889 related articles for article (PubMed ID: 19372173)
1. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Why empirical therapy?
Klastersky J
J Antimicrob Chemother; 2009 May; 63 Suppl 1():i14-5. PubMed ID: 19372173
[TBL] [Abstract][Full Text] [Related]
2. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Summary and comments.
Sinkó J; Kullberg BJ; Edwards JE; Anaissie E
J Antimicrob Chemother; 2009 May; 63 Suppl 1():i41-3. PubMed ID: 19372182
[No Abstract] [Full Text] [Related]
3. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Where do we go from here?
Pizzo PA
J Antimicrob Chemother; 2009 May; 63 Suppl 1():i16-7. PubMed ID: 19372174
[TBL] [Abstract][Full Text] [Related]
4. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Why monotherapy?
Williams KJ
J Antimicrob Chemother; 2009 May; 63 Suppl 1():i18-20. PubMed ID: 19372175
[TBL] [Abstract][Full Text] [Related]
5. [Antimicrobial prophylaxis and therapy in neutropenia].
Link H
Mycoses; 2003; 46 Suppl 2():21-32. PubMed ID: 15055140
[TBL] [Abstract][Full Text] [Related]
6. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Fever and neutropenia: the early years.
Bodey GP
J Antimicrob Chemother; 2009 May; 63 Suppl 1():i3-13. PubMed ID: 19372179
[TBL] [Abstract][Full Text] [Related]
7. [Application of the concepts of evidence-based medicine to the evidence on the treatment of febrile neutropenia].
Jarque I; Sanz MA
Enferm Infecc Microbiol Clin; 1999; 17 Suppl 2():95-102. PubMed ID: 10605194
[TBL] [Abstract][Full Text] [Related]
8. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.
Tamura K
Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072
[TBL] [Abstract][Full Text] [Related]
9. Three-day treatment with imipenem for unexplained fever during prolonged neutropaenia in haematology patients receiving fluoroquinolone and fluconazole prophylaxis: a prospective observational safety study.
Slobbe L; Waal Lv; Jongman LR; Lugtenburg PJ; Rijnders BJ
Eur J Cancer; 2009 Nov; 45(16):2810-7. PubMed ID: 19647995
[TBL] [Abstract][Full Text] [Related]
10. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Management of mycoses in neutropenic patients: a brief history, 1960-2008.
Bennett JE
J Antimicrob Chemother; 2009 May; 63 Suppl 1(Suppl 1):i23-6. PubMed ID: 19372177
[TBL] [Abstract][Full Text] [Related]
11. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Moulds: diagnosis and treatment.
Verweij PE; Maertens J
J Antimicrob Chemother; 2009 May; 63 Suppl 1():i31-5. PubMed ID: 19372180
[TBL] [Abstract][Full Text] [Related]
12. Empiric treatment of fungal infections in the neutropenic host. Review of the literature and guidelines for use.
Sugar AM
Arch Intern Med; 1990 Nov; 150(11):2258-64. PubMed ID: 2241435
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial prophylaxis for infection in neutropenic patients.
Bodey GP
Curr Clin Top Infect Dis; 1988; 9():1-43. PubMed ID: 3077285
[No Abstract] [Full Text] [Related]
14. Empirical antifungal therapy in selected patients with persistent febrile neutropenia.
Aguilar-Guisado M; Espigado I; Cordero E; Noguer M; Parody R; Pachón J; Cisneros JM
Bone Marrow Transplant; 2010 Jan; 45(1):159-64. PubMed ID: 19525983
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline.
Flowers CR; Seidenfeld J; Bow EJ; Karten C; Gleason C; Hawley DK; Kuderer NM; Langston AA; Marr KA; Rolston KV; Ramsey SD
J Clin Oncol; 2013 Feb; 31(6):794-810. PubMed ID: 23319691
[TBL] [Abstract][Full Text] [Related]
16. Wait and see or rush and switch? New questions for the management of patients with febrile neutropenia receiving antifungal prophylaxis.
Karthaus M; Hentrich M
Mycoses; 2011 Jan; 54 Suppl 1():1-6. PubMed ID: 21126265
[TBL] [Abstract][Full Text] [Related]
17. [Antibiotics and antimycotics in oncology].
Krcméry V
Vnitr Lek; 1991; 37(7-8):695-702. PubMed ID: 1755212
[TBL] [Abstract][Full Text] [Related]
18. Empirical antifungal therapy in patients with neutropenia and persistent or recurrent fever of unknown origin.
Martino R; Viscoli C
Br J Haematol; 2006 Jan; 132(2):138-54. PubMed ID: 16398648
[TBL] [Abstract][Full Text] [Related]
19. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Mucositis: from febrile neutropenia to febrile mucositis.
Blijlevens NM; Logan RM; Netea MG
J Antimicrob Chemother; 2009 May; 63 Suppl 1():i36-40. PubMed ID: 19372181
[TBL] [Abstract][Full Text] [Related]
20. Combination and single-agent empirical antibacterial therapy for febrile cancer patients with neutropenia and mucositis.
Shenep JL
NCI Monogr; 1990; (9):117-22. PubMed ID: 2342588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
